Cancer statistics, 2020

Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal, Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.

Keywords: cancer cases; cancer statistics; death rates; incidence; mortality.

© 2020 American Cancer Society.

References

    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Total US (1990-2017) <Early release with Vintage 2017 Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2019; underlying mortality data provided by National Center for Health Statistics, 2019.
    1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97(suppl 12):3133-3275.
    1. Murphy SL, Kochanek KD, Xu J, Heron M. Deaths: Final Data for 2012. National Vital Statistics Reports. Vol 63. No 9. National Center for Health Statistics; 2015.
    1. Sherman R, Firth R, De P, et al. Cancer In North America, 2012-2016. Vol 3. Registry-Specific Cancer Mortality in the United States and Canada. North American Association of Central Cancer Registries Inc; 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov. 2018 Sub (1975-2016) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2018 Sub (2000-2016) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2019.
    1. Statistical Research and Applications Branch, National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software. Version 6.7.7. Surveillance Research Program, Statistical Methodology and Applications, National Cancer Institute; 2019.
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute; 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-CiNA Analytic File, 1995-2016, for Expanded Races, Custom File With County, ACS Facts and Figures projection Project (Which Includes Data from CDC's National Program of Cancer Registries [NPCR], CCCR's Provincial and Territorial Registries, and the NCI's Surveillance, Epidemiology and End Results [SEER] Registries). North American Association of Central Cancer Registries; 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-CiNA Analytic File, 1995-2016, for NHIAv2 Origin, Custom File With County, ACS Facts and Figures projection Project (which includes data from CDC's National Program of Cancer Registries [NPCR], CCCR's Provincial and Territorial Registries, and the NCI's Surveillance, Epidemiology and End Results [SEER] Registries). North American Association of Central Cancer Registries; 2019.
    1. Sherman R, Firth R, De P, et al. Cancer in North America: 2012-2016. Vol 1. Combined Cancer Incidence for the United States, Canada and North America. North American Association of Central Cancer Registries Inc; 2019.
    1. Sherman R, Firth R, De P, et al. Cancer in North America: 2012-2016. Vol 2. Registry-Specific Cancer Incidence in the United States and Canada. North American Association of Central Cancer Registries Inc; 2019.
    1. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005;103:1457-1467.
    1. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. World Health Organization; 2000.
    1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Rev. Vols I-III. World Health Organization; 2011.
    1. Surveillance Research Program, National Cancer Institute. SEER*Stat Software. Version 8.3.6. Surveillance Research Program, National Cancer Institute; 2019.
    1. Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program. Version 4.7.0.0. Statistical Research and Applications Branch, National Cancer Institute; 2019.
    1. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94:1537-1545.
    1. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007;57:30-42.
    1. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer. 2012;118:1100-1109.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Populations-Total US (1969-2017) <Katrina/Rita Adjustment>-Linked To County Attributes-Total US, 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 21 Regs Limited-Field Research Data + Hurricane Katrina Impacted Louisiana Cases with Delay-Adjustment, Malignant Only, Nov. 2018 Sub (2000-2016) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2019.
    1. Chen HS, Portier K, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part I: evaluation of temporal projection methods for mortality. Cancer. 2012;118:1091-1099.
    1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-638.
    1. Wiren S, Haggstrom C, Ulmer H, et al. Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes Control. 2014;25:151-159.
    1. Walter RB, Brasky TM, Buckley SA, Potter JD, White E. Height as an explanatory factor for sex differences in human cancer. J Natl Cancer Inst. 2013;105:860-868.
    1. Williams LA, Richardson M, Marcotte EL, Poynter JN, Spector LG. Sex ratio among childhood cancers by single year of age. Pediatr Blood Cancer. 2019;66:e27620.
    1. Ward E, Sherman RL, Henley SJ, et al. Annual Report to the Nation on the Status of Cancer, 1999-2015, Featuring Cancer in Men and Women Ages 20-49. J Natl Cancer Inst. Published online May 30, 2019. doi:10.1093/jnci/djz106
    1. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
    1. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
    1. Negoita S, Feuer EJ, Mariotto A, et al. Annual Report to the Nation on the Status of Cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124:2801-2814.
    1. U.S. Preventive Services Task Force. Draft Recommendation Statement: Screening for Prostate Cancer. Accessed September 27, 2017.
    1. Fenton J, Weyrick M, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: a systematic evidence review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality; 2017. AHRQ Pub. No. 17-05229-EF-1.
    1. U.S. Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:1901-1913.
    1. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018;27:1214-1222.
    1. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354-361.
    1. Clarke MA, Devesa SS, Harvey SV, Wentzensen N. Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J Clin Oncol. 2019;37:1895-1908.
    1. Morris LG, Tuttle RM, Davies L. Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol Head Neck Surg. 2016;142:709-711.
    1. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023-1029.
    1. Harris JE. Cigarette smoking among successive birth cohorts of men and women in the United States during 1900-80. J Natl Cancer Inst. 1983;71:473-479.
    1. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in southern and midwestern states. J Clin Oncol. 2012;30:2739-2744.
    1. Jemal A, Miller KD, Ma J, et al. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 2018;378:1999-2009.
    1. Thrift AP, Gudenkauf FJ. Melanoma incidence among non-Hispanic whites in all 50 US states from 2001 through 2015. J Natl Cancer Inst. Published online July 25, 2019. doi:10.1093/jnci/djz153
    1. Islami F, Sauer AG, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable factors in the United States in 2014. CA Cancer J Clin. 2018;68:31-54.
    1. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62:1353-1363.
    1. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis. 2014;34:22-29.
    1. Jemal A, Fedewa SA. Recent hepatitis C virus testing patterns among baby boomers. Am J Prev Med. 2017;53:e31-e33.
    1. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. Viral hepatitis surveillance, United States, 2017. Accessed October 11, 2019.
    1. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;109(9).
    1. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother's cancer. Cancer. 2016;122:2787-2798.
    1. Fiorica JV. The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol. 2003;90(3 pt 2):S16-S21.
    1. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103:1258-1264.
    1. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010;37:202-215.
    1. Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186-e193.
    1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
    1. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30:1162-1169.
    1. Huo J, Shen C, Volk RJ, Shih Y. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake. JAMA Intern Med. 2017;177:439-441.
    1. Richards TB, Doria-Rose VP, Soman A, et al. Lung cancer screening inconsistent with U.S. Preventive Services Task Force recommendations. Am J Prev Med. 2019;56:66-73.
    1. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer?JAMA. 2000;283:2975-2978.
    1. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-181.
    1. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-455.
    1. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29-39.
    1. Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother. 2018;67:1833-1844.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data, Nov. 2018 Sub (1973-2016) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2019.
    1. Enewold L, Sharon E, Harlan LC. Metastatic melanoma: treatment and survival in the US after the introduction of ipilimumab and vemurafenib. Oncol Res Treat. 2017;40:174-183.
    1. Crocetti E, Fancelli L, Manneschi G, et al. Melanoma survival: sex does matter, but we do not know how. Eur J Cancer Prev. 2016;25:404-409.
    1. Sommers BD, Musco T, Finegold K, Gunja MZ, Burke A, McDowell AM. Health reform and changes in health insurance coverage in 2014. N Engl J Med. 2014;371:867-874.
    1. Heron M, Anderson RN. Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality. National Center for Health Statistics; 2016. NCHS Data Brief No. 254.
    1. Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65:457-480.
    1. Torre LA, Sauer AM, Chen MSJr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66:182-202.
    1. Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. Ann Intern Med. 2018;169:684-693.
    1. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med. 2019;123:316-323.
    1. Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
    1. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases. 2018 Adolescent Human Papillomavirus (HPV) Vaccination Coverage Report. Accessed September 29, 2019.
    1. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures. American Cancer Society; 2019.
    1. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
    1. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
    1. Nelson DE, Mowery P, Asman K, et al. Long-term trends in adolescent and young adult smoking in the United States: metapatterns and implications. Am J Public Health. 2008;98:905-915.
    1. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data, 2018. Accessed September 27, 2019.
    1. Drolet M, Benard E, Perez N, Brisson M, HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394:497-509.
    1. Nguyen BT, Han X, Jemal A, Drope J. Diet quality, risk factors and access to care among low-income uninsured American adults in states expanding Medicaid vs. states not expanding under the Affordable Care Act. Prev Med. 2016;91:169-171.
    1. Sommers BD, Gawande AA, Baicker K. Health insurance coverage and health-what the recent evidence tells us. N Engl J Med. 2017;377:586-593.
    1. Kantarjian HM, Keating MJ, Freireich EJ. Toward the potential cure of leukemias in the next decade. Cancer. 2018;124:4301-4313.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する